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Abstract 
The aim of present study was to develop simple and economical UV- Spectrophotometric method for estimation of 
Risperidone using Area Under Curve (AUC) technique with the application of hydrotropic solubilisation phenomenon. 
Aqueous urea solution (30% v/v) was used as a hydrotropic agent for solubilising risperidone. The method is based upon 
integration of area under curve for analysis of risperidone in the wavelength range of 265.0 - 287.40 nm. The drug followed 
linearity in the concentration range of 4 - 24 µg/mL with correlation coefficient value r
2
 > 0.99. The proposed method was 
validated for accuracy, precision, repeatability and ruggedness as per ICH guidelines. The proposed method was applied for 
qualitative and quantitative estimation of risperidone in pharmaceutical formulation and results were found in good 
agreement with the label claimed. This developed method can be used for routine analysis of Risperidone in bulk and 
tablets. 
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1. Introduction 
Risperidone (RIS) is chemically 4-[2-[4-(6-
fluorobenzo[d]isoxazol-3-yl)-1-piperidyl] ethyl]- 
3-methyl- 2,6-diazabicyclo[4.4.0]deca-1,3-dien-5-one [1]. 
It is an atypical antipsychotic drug which is mainly used to 
treat schizophrenia. It is a dopamine antagonist possessing 
anti-serotonergic, anti-adrenergic and anti- histaminergic 
properties. It is practically insoluble in water [2]. Several 
methods such as HPLC-MS/MS [3], RP-HPLC [4-6], 
HPTLC [7] and UV-spectrophotometric [8] have been 
reported for the estimation of risperidone in bulk, 
pharmaceutical formulation and biological fluids. These all 
methods involve the use of organic solvents for solubilising 
the drug.  
Hydrotropic agents are anionic organic salts 
which, at high concentrations, considerably enhance the 
aqueous solubility of poorly soluble solutes. Hydrotropy is 
a solubilization phenomenon whereby addition of large 
amount of second solute results in an increase in the 
aqueous solubility of another solute. However, the term has 
been used in the literature to designate non-micelle-
forming substances, either liquids or solids, organic or 
inorganic, capable of solubilizing insoluble compounds [9, 
10]. Hydrotropy is suggested to be superior to other 
solubilization method, such as miscibility, micellar 
solubilization, co-solvency and salting in, because the 
solvent character is independent of pH, has high selectivity 
and does not require emulsification.[11] 
To our notice, so far no UV- spectrophotometric 
method using Area Under Curve (AUC) has been reported 
for the determination of risperidone in bulk and tablets. 
Therefore, an attempt has been made to develop 
UV- spectrophotometric method using Area Under Curve 
(AUC) technique with the application of hydrotropic 
solubilisation phenomenon for the determination of 
risperidone in bulk and tablets. Further, to validate 
developed method for accuracy, precision, repeatability, 
and ruggedness as per ICH guidelines [12]. 
 
2. Materials and Methods   
2.1 Chemicals and Reagents  
Risperidone working standards were obtained as 
generous gifts from Wockhardt ltd. Aurangabad, India. 
Urea (A.R. Grade) was purchased from Merck Ltd., Worli, 
Mumbai, India. Tablets (RESPIDON) was purchased from 
local market, containing RIS 4 mg per tablet. 
 
 
2.2 Instrumentation  
For proposed UV- Spectrophotometry method, 
UV-Visible spectrophotometer (Shimadzu 2450 with UV 
Probe 2.21 software) and a pair of 1 cm matched quartz 
cells were used.  
2.3 Preparation of stock Standard Solutions  
As risperidone is practically insoluble in water; 
urea is used as hydrotropic agent for enhancing the 
solubility of drug in water.  
Stock standard solution of 100 μg/ml of 
risperidone was prepared in aqueous urea solution (30 % 
v/v). The working standards were prepared by dilution of 
the stock standard solution. 
2.4 UV - Spectrophotometry Method using AUC 
Technique:  
It involves the calculation of integrated value of 
absorbance with respect to the wavelength between the two 
selected wavelengths λ1 and λ2. From the spectrum of 
risperidone, the AUC in the wavelengths between 265 - 
287.40 nm was selected for the analysis. 
2.5 Linearity studies 
An appropriate volumes of risperidone in the 
range of 0.4 – 2.4 mL were transferred into series  of six 
separate 10 mL volumetric flasks and volume was made up 
to mark with 30 % aqueous  urea solution to get 
concentrations in the range of 04 – 24 μg/mL. The AUC 
between the wavelength ranges of 265 - 287.40 nm was 
measured and calibration curves were plotted as 
concentrations versus AUC. 
2.6 Analysis of Marketed Formulation 
To determine the content of risperidone in 
marketed formulation (label claim: 4 mg risperidone per 
tablet); twenty tablets were accurately weighed, their mean 
weight determined and crushed into fine powder. A 
quantity of tablet powder equivalent  to 10 mg of 
risperidone was transfer into 100 ml volumetric flask 
containing 50 mL of 30 % urea solution, sonicated for  15   
min, volume was made up to the mark using same solvent  
and filtered through Whatmann filter paper  No. 41. An 
appropriate volume was further diluted to 10 mL mark. The 
analysis was repeated for six times and determination were 
done using calibration curve. The results are shown in 
Table 1. 
2.7 Validation of Method 
The method was validated for accuracy, precision, 
sensitivity and ruggedness as per International conference 
on Harmonization (ICH) guidelines.  
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2.7.1 Accuracy:  
The accuracy of the proposed method was 
evaluated using recovery studies at three different levels 
i.e. 80%, 100% and 120%. To the pre-analyzed sample 
solutions (8 𝜇g/mL), known amounts of stock standard 
solutions were added at different levels, the solutions were 
reanalyzed by the proposed method and area under curve 
was recorded at selected wavelengths. The experiments 
were repeated for three times. 
2.7.2 Precision:  
The precision of the method is studied as 
repeatability, intra-day and inter-day precision. 
Repeatability was determined by analyzing RIP (12 
μg/mL) for six times.  
Intra-day precision was determined by analyzing the 8, 12, 
and 16 μg/mL of risperidone for three times in the same 
day.  Inter-day precision was determined by analyzing the 
same concentration of the solutions daily for three days.  
2.7.3 Sensitivity:  
The sensitivity of proposed method was estimated 
in terms of limit of detection (LOD) and limit of 
quantification (LOQ) which were calculated using 
formulae “LOQ = 10 ×𝑁/𝐵” and “LOD = 3.3 ×𝑁/𝐵,” 
where “𝑁” is standard deviation of the amplitudes or peak 
areas of the RIS (𝑛 = 3), taken as a measure of noise, and 
“𝐵” is the slope of the corresponding calibration curve. For 
determining sensitivity different volume of stock solution 
in the range 4 - 8 µg/mL was prepared. The procedure was 
repeated in triplicate. 
2.7.4 Ruggedness:  
The ruggedness of the proposed method is 
determined by analysis of aliquots (12 µg/mL) from 
homogenous sample lots by two analyst using same 
operational and environmental conditions.  
 
3. Results and Discussion 
Risperidone is practically insoluble in water; 
therefore, 30% urea solution as hydrotropic agent was used 
for solubilisation of risperidone. There was no interference 
of urea solution in the estimation of risperidone in bulk as 
well as tablets. Risperidone obeyed linearity in the 
concentration range of 04 - 24 μg/mL, with correlation 
coefficient (r2 > 0.99). Marketed formulation was 
analyzed. The results showed good agreement between the 
amounts estimated, and those claimed on label. Percent 
label claims are very close to 100, with low values of 
standard deviation, % coefficient of variation, and standard 
error. The results are shown in Table 1. Precision was 
studied as repeatability (% RSD < 2) and inter and intra-
day variations (%RSD < 2). The accuracy of method was 
determined by calculating mean percentage recovery. It 
was determined at 80,100 and 120 % level. The ruggedness 
of the methods was studied by two different analysts using 
the same operational and environmental conditions. The 
results for % recovery, precision, repeatability and 
ruggedness are shown in Table 2. 
 
Table 1: Analysis of tablets 
 
Drug Amount 
taken 
(µg/mL) 
Amount found ± 
S.D. 
(µg/mL) 
%Amount 
found ± S.D. 
RIS 12 11.92 ± 0.18 99.34 ± 1.56 
 
 
 
Table 2: Summary of Validation parameters 
 
Parameters Results 
Linearity (range) 04 - 24µg/mL 
y = mx + C Y = 0.1731x - 0.0166 
Correlation coefficient 0.999 
% Recovery (n=9) 99.37 – 99.75% 
Precision (% R.S.D.)  
Intra-Day (n=9) 0.84 - 1.65 
Inter-Day (n =9) 0.94 - 1.87 
Repeatability (n=6) 0.87 
Ruggedness (n=6)  
Analyst I 99.49 ± 1.31 
Analyst II 99.47 ± 1.64 
n= number of estimations 
 
 
Fig. 1: UV- Spectrum of risperidone in 30 % w/v urea 
solution showing the selection of area under curve 
between 265 - 287.40 nm 
 
Figure 2: Linearity curve for Risperidone 
 
References 
[1] British Pharmacopoeia 2005 volume I, pp. 848 
[2] Sweetman S. C., Martinedale: The complete drug 
reference, 35
th 
edn, Pharmaceutical Press, London, 
2007, 2448 
[3] Huang M, Shentu J, Chen J, Liu J, Zhou H. 
Determination of risperidone in human plasma by 
HPLC-MS/MS and its application to a 
Research Article                                                                                                Amod S. Patil et al /2015
 
 
                                                            60 
 
pharmacokinetic study in Chinese volunteers.  J 
Zhejiang Univ Sci B 2008; 9(2): 114-120 
[4] Baldania SL, Bhatt KK, Mehta RS, Shah DA. RP-
HPLC Estimation of Risperidone in Tablet Dosage 
Forms. Indian J Pharm Sci 2008; 70 (4): 494 – 497. 
[5] Suthar AP, Dubey SA, Patel SR, Shah AM. 
Determination of Risperidone and forced degradation 
behavior by HPLC in tablet dosage form. Int J Pharm 
Tech Res 2009; 1(3): 568-574. 
[6] Dedania ZR, Dedania RR, Sheth NR, Patel JB, Patel 
B. Stability Indicating HPLC Determination of 
Risperidone in Bulk Drug and Pharmaceutical 
Formulations. Int J Anal Chem. Article ID 124917, 
2011, 6 pages doi:10.1155/2011/124917 
[7] Maalanka A, Krzek J, Patrzalek A. Determination of 
Risperidone in Tablets in the Presence of Its 
Degradation Products and Placebo-Derived 
Constituents. Acta Pol. Pharm. 2009; 66 (5): 461- 470. 
[8] Vasagam GA, Smith AA, Nawas C, Kumar MS, 
Muthu AK, Manavalan R. Development of analytical 
method for Risperidone by UV Spectrophotometry 
using methanol as a solvent. Der Pharma Chem 2010; 
2(3): 309-315. 
[9] Neuberg C. Hydrotropy. Biochem Z 1916; 76: 107-
109. 
[10] Saleh AM, El-Khordagui LK. Hydrotropic agents: a 
new definition. Int J Pharmaceutics 1985; 24: 231-
238. 
[11] Jain P, Goel A, Sharma S, Parmar M. Solubility 
Enhancement Techniques with Special Emphasis on 
Hydrotrophy. Int J  Pharma Professional’s Res.2010; 
1(1):  34-45. 
[12] ICH, Q2 (R1) Validation of analytical procedures: 
Text and methodology, International Conference on 
Harmonization. 2005. 
 
 
